Grant ID RP180073
Awarded On February 21, 2018
Title Myeloid support of refractory and aggressive T-ALL at distinct tumor sites
Program Academic Research
Award Mechanism Individual Investigator Research Awards for Cancer in Children and Adolescents
Institution/Organization The University of Texas at Austin
Principal Investigator/Program Director Lauren Ehrlich
Cancer Sites Leukemia, Lymphoma
Contracted Amount $1,200,000
Lay Summary

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with the T cell subtype (T-ALL) representing ~15% of pediatric ALL cases. Current chemotherapeutic regimens have improved five-year event-free survival rates to ~80% in children. However, these therapies are toxic, often resulting in life-long morbidities. Furthermore, prognosis is dismal for ~20% of patients who relapse or fail to respond to chemotherapy, as there are no alternative treatments. Therefore, there is an unmet clinical need to develop improved T-ALL therapies. Despite the fact that molecular changes driving T-ALL have been identified, this knowledge has not yet translated into successful therapeutics....

Read More